I85PREP
⌘ K
PBP study materials
PBP study resources

PBP practice questions

One question at a time. Build your PBP understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Foundational Knowledge and Terminology

In pharmacogenomics, which term describes a heritable DNA variant present in at least 1% of a population?

  1. Polymorphism Correct answer.
  2. Haplotype
  3. Mutation
  4. Copy-number variant

Explanation

A polymorphism is a genetic variant with a population frequency of roughly 1% or greater, which distinguishes it from a rare mutation. Haplotypes and copy-number variants are structural or positional concepts and are not defined by this frequency threshold.

Question 2Foundational Knowledge and Terminology

A drug is a prodrug that requires bioactivation by CYP2D6. A patient carries two no-function CYP2D6 alleles. According to standard pharmacogenetic phenotype terminology, how is this patient classified?

  1. Poor metabolizer Correct answer.
  2. Ultrarapid metabolizer
  3. Intermediate metabolizer
  4. Normal metabolizer

Explanation

Two no-function alleles produce absent enzyme activity, which is the standard definition of a poor metabolizer. This phenotype matters clinically because prodrugs needing CYP2D6 activation may fail to form active drug.

Question 3Foundational Knowledge and Terminology

Which term refers to the study of how an individual's inherited genetic variants affect response to a specific drug?

  1. Pharmacoepidemiology
  2. Pharmacovigilance
  3. Pharmacodynamics
  4. Pharmacogenetics Correct answer.

Explanation

Pharmacogenetics examines how inherited variation in single genes influences drug response and disposition. The other disciplines address population-level drug effects, adverse-event detection, or drug action at the target.

Question 4Foundational Knowledge and Terminology

A variant changes a drug target so the drug binds with lower affinity but the receptor still signals normally when activated. Which term best describes this phenomenon?

  1. Pharmacodynamic alteration Correct answer.
  2. Bioavailability change
  3. Protein-binding displacement
  4. Pharmacokinetic alteration

Explanation

A change at the drug target affecting binding or signal transduction is a pharmacodynamic effect, because it alters what the drug does to the body. Pharmacokinetic terms describe what the body does to the drug.

Question 5Foundational Knowledge and Terminology

Which term describes the fraction of an administered dose that reaches systemic circulation unchanged?

  1. Clearance
  2. Half-life
  3. Bioavailability Correct answer.
  4. Volume of distribution

Explanation

Bioavailability quantifies the proportion of dose reaching the systemic circulation intact, and it is reduced by first-pass metabolism. Clearance, volume of distribution, and half-life are separate pharmacokinetic parameters.

Question 6Foundational Knowledge and Terminology

Which enzyme family is responsible for the majority of phase I oxidative drug metabolism in humans?

  1. Cytochrome P450 Correct answer.
  2. N-acetyltransferases
  3. Glucuronosyltransferases
  4. Sulfotransferases

Explanation

Cytochrome P450 enzymes, especially CYP3A4, mediate most phase I oxidative metabolism. The other listed families catalyze phase II conjugation reactions.

Question 7Foundational Knowledge and Terminology

Which term describes a genetic variant that is common in one ancestral population but rare or absent in another, affecting drug dosing recommendations?

  1. Genetic drift
  2. Population-specific allele frequency difference Correct answer.
  3. Pleiotropy
  4. Linkage disequilibrium

Explanation

Allele frequencies for pharmacogenes can differ substantially among ancestral populations, which is why some dosing guidelines are ancestry-specific. Linkage disequilibrium, drift, and pleiotropy describe different genetic phenomena.

Question 8Foundational Knowledge and Terminology

Which term describes an unexpected, harmful response to a drug occurring at doses normally used in humans?

  1. Adverse drug reaction Correct answer.
  2. Therapeutic failure
  3. Drug interaction
  4. Idiosyncratic metabolism

Explanation

An adverse drug reaction is a harmful response at normal therapeutic doses, and many such reactions have pharmacogenetic contributors. Therapeutic failure and drug interaction describe different clinical outcomes.

Question 9Foundational Knowledge and Terminology

A patient has one normal-function and one decreased-function allele for a pharmacogene. What phenotype is generally assigned under standard diplotype-to-phenotype translation?

  1. Poor metabolizer
  2. Intermediate metabolizer Correct answer.
  3. Normal metabolizer
  4. Ultrarapid metabolizer

Explanation

Combining one normal-function allele with one decreased-function allele typically yields intermediate activity. Poor metabolizer requires two no-function alleles, and normal metabolizer requires full activity.

Question 10Foundational Knowledge and Terminology

A drug is metabolized by CYP2C19, and the patient is a CYP2C19 poor metabolizer taking a standard dose of the active drug. What is the most likely pharmacokinetic consequence?

  1. Decreased parent drug exposure and risk of therapeutic failure
  2. Unchanged exposure because CYP2C19 is not inducible
  3. Reduced absorption from the gastrointestinal tract
  4. Increased parent drug exposure and risk of toxicity Correct answer.

Explanation

When the active drug is cleared by CYP2C19, absent enzyme activity reduces metabolism and raises parent drug concentrations. This increases the risk of concentration-dependent adverse effects unless the dose is adjusted.

Question 11Foundational Knowledge and Terminology

Which term describes the situation in which a drug's effect is mediated by a metabolite rather than the parent compound?

  1. Inactive metabolite
  2. Parent drug
  3. Prodrug
  4. Active metabolite Correct answer.

Explanation

An active metabolite is a biotransformation product that retains or acquires pharmacologic activity. A prodrug is the administered inactive precursor, and an inactive metabolite lacks activity.

Question 12Foundational Knowledge and Terminology

Which term describes the phenomenon in which one variant affects the expression or function of a neighboring gene because they are inherited together on the same haplotype block?

  1. Penetrance
  2. Epistasis
  3. Linkage disequilibrium Correct answer.
  4. Pleiotropy

Explanation

Linkage disequilibrium means alleles at nearby loci co-occur more often than expected by chance, so a tag variant can mark a functional variant. Epistasis, pleiotropy, and penetrance describe different genetic relationships.

Question 13Foundational Knowledge and Terminology

A drug label states that CYP2D6 ultrarapid metabolizers may have reduced efficacy because the drug is converted to an inactive metabolite. Which genotype is most consistent with this phenotype?

  1. One reduced-function and one no-function allele
  2. Two normal-function alleles without duplication
  3. Two no-function CYP2D6 alleles
  4. CYP2D6 gene duplication with two functional copies Correct answer.

Explanation

Gene duplication yielding more than two functional copies produces increased enzyme activity, the ultrarapid metabolizer phenotype. This accelerates conversion of the drug to inactive metabolite and can lower efficacy.

Question 14Foundational Knowledge and Terminology

Which term refers to the dose or exposure range associated with the best balance of efficacy and toxicity for a given drug?

  1. Bioequivalence
  2. Loading dose
  3. Steady state
  4. Therapeutic window Correct answer.

Explanation

The therapeutic window spans concentrations between the minimum effective and minimum toxic thresholds. Pharmacogenetic variation can narrow or shift this window for an individual patient.

Question 15Foundational Knowledge and Terminology

A patient is a CYP2C9 poor metabolizer taking warfarin, a narrow-therapeutic-index substrate. What is the most appropriate interpretation for dosing?

  1. Higher sensitivity to warfarin, so lower initial doses and closer INR monitoring are warranted Correct answer.
  2. A higher initial dose is needed to overcome reduced metabolism
  3. No dose change is needed because warfarin is monitored by INR alone
  4. CYP2C9 genotype affects only warfarin absorption

Explanation

Reduced CYP2C9 activity increases warfarin exposure and bleeding risk, so genotype-guided care uses lower initial doses and frequent INR monitoring. INR monitoring complements but does not replace genotype information.

Question 16Foundational Knowledge and Terminology

Which term describes a variant that changes an amino acid in the encoded protein and may alter drug binding?

  1. Missense variant Correct answer.
  2. Splice-site variant
  3. Synonymous variant
  4. Frameshift variant

Explanation

A missense variant substitutes one amino acid for another, which can change protein structure or drug binding. Synonymous variants do not change the amino acid sequence, while frameshift and splice-site variants disrupt reading frame or splicing.

Question 17Foundational Knowledge and Terminology

Which term describes the use of genetic information to select the drug or dose most likely to be safe and effective for an individual patient?

  1. Therapeutic drug monitoring
  2. Empiric prescribing
  3. Phenoconversion
  4. Genotype-guided prescribing Correct answer.

Explanation

Genotype-guided prescribing uses a patient's pharmacogenetic result to choose drug or dose before or during therapy. Therapeutic drug monitoring measures concentrations, and phenoconversion describes a phenotype change from nongenetic factors.

Question 18Foundational Knowledge and Terminology

Which term describes the change in a patient's metabolizer phenotype caused by a strong CYP inhibitor, despite a normal genotype?

  1. Phenoconversion Correct answer.
  2. Loss of heterozygosity
  3. Genoconversion
  4. Haploinsufficiency

Explanation

Phenoconversion occurs when nongenetic factors such as coadministered inhibitors make a genotypic normal metabolizer behave like a poor metabolizer. It is important because genotype alone may mispredict current enzyme activity.

Question 19Foundational Knowledge and Terminology

A pharmacogene has a variant that creates a premature stop codon, and the resulting protein lacks catalytic activity. Which variant class best describes this?

  1. Missense variant
  2. Synonymous variant
  3. Nonsense variant Correct answer.
  4. Intronic variant

Explanation

A nonsense variant introduces a premature stop codon and typically produces a truncated, nonfunctional protein. Missense variants substitute amino acids, and synonymous variants do not change the protein sequence.

Question 20Foundational Knowledge and Terminology

Which term describes the proportion of individuals carrying a genotype who actually express the associated phenotype?

  1. Expressivity
  2. Penetrance Correct answer.
  3. Allele frequency
  4. Heritability

Explanation

Penetrance is the fraction of genotype carriers who show the phenotype, which can be incomplete in pharmacogenetics. Expressivity describes variation in severity among those affected.

Question 21Foundational Knowledge and Terminology

A drug is a prodrug activated by CYP2D6, and the patient is a CYP2D6 ultrarapid metabolizer. Which clinical concern is most consistent with this genotype?

  1. Reduced absorption of the prodrug
  2. Excessive formation of active metabolite and increased toxicity risk Correct answer.
  3. No effect because prodrugs bypass metabolism
  4. Reduced formation of active metabolite and therapeutic failure

Explanation

Ultrarapid metabolism of a prodrug increases conversion to the active metabolite, which can raise toxicity risk. The opposite concern, therapeutic failure, applies to ultrarapid metabolism of active drugs cleared to inactive metabolites.

Question 22Foundational Knowledge and Terminology

A patient carries a CYP2D6 genotype predicting normal metabolism but takes a strong CYP2D6 inhibitor. How should the genotype result be interpreted for a CYP2D6 substrate?

  1. The patient may behave like a poor metabolizer because of phenoconversion Correct answer.
  2. The genotype result should be discarded because it is invalid
  3. The inhibitor increases CYP2D6 activity and requires higher doses
  4. Genotype guarantees normal metabolism regardless of comedications

Explanation

Strong inhibition can suppress enzyme activity so that a genotypic normal metabolizer functions like a poor metabolizer, a phenomenon called phenoconversion. Prescribing decisions should combine genotype with interacting comedications.

Question 23Foundational Knowledge and Terminology

A variant lies in the promoter region of a pharmacogene and reduces transcription without changing the amino acid sequence. Which term best describes this functional consequence?

  1. Gene duplication
  2. Altered gene expression Correct answer.
  3. Frameshift truncation
  4. Missense substitution

Explanation

Regulatory variants in promoter regions can change the amount of mRNA and protein produced, altering expression rather than protein sequence. This can change drug metabolism without any amino acid substitution.

Question 24Foundational Knowledge and Terminology

A drug has a narrow therapeutic index and is cleared by CYP2C19. A patient is a CYP2C19 poor metabolizer, and the drug is also a strong CYP2C19 inhibitor. Which conclusion is most defensible?

  1. Genotype and inhibitor effects cancel, so standard dosing is appropriate
  2. The inhibitor will offset the genotype and restore normal clearance
  3. The genotype affects only the drug's absorption
  4. Both factors reduce clearance, so exposure may be markedly increased and dose reduction or avoidance should be considered Correct answer.

Explanation

Genetic loss of function and pharmacologic inhibition both reduce CYP2C19-mediated clearance, and their effects are additive rather than opposing. For a narrow-therapeutic-index drug, this combination raises toxicity risk and supports avoidance or substantial dose reduction.

Question 25Foundational Knowledge and Terminology

Which statement best distinguishes pharmacogenomics from pharmacogenetics?

  1. The terms describe unrelated fields with no overlap
  2. Pharmacogenomics considers the genome-wide contribution to drug response, while pharmacogenetics often focuses on single-gene effects Correct answer.
  3. Pharmacogenomics applies only to cancer drugs, while pharmacogenetics applies only to antivirals
  4. Pharmacogenetics concerns only drug absorption, while pharmacogenomics concerns only metabolism

Explanation

Pharmacogenomics is broader and examines genome-wide influences on drug response, while pharmacogenetics traditionally studies individual genes. In practice the terms are often used interchangeably.

Question 26Foundational Knowledge and Terminology

A drug's effect depends on binding to a protein target whose gene carries a missense variant. Which term best describes the protein target in this relationship?

  1. Prodrug
  2. Receptor tyrosine kinase
  3. Pharmacogene Correct answer.
  4. Excipient

Explanation

A pharmacogene is any gene whose variation influences drug response, including genes encoding drug targets, metabolizing enzymes, and transporters. Because the missense variant in the target gene alters binding and therefore response, that gene is a pharmacogene regardless of whether it encodes an enzyme or a receptor.

Question 27Foundational Knowledge and Terminology

A drug requires metabolic activation by a phase I enzyme before it can bind its target. Which term describes the parent compound in this situation?

  1. Prodrug Correct answer.
  2. Active metabolite
  3. Substrate inhibitor
  4. Competitive antagonist

Explanation

A prodrug is a compound that must undergo biotransformation, often by phase I enzymes, to produce the active species. The parent molecule therefore has little or no intrinsic activity, and the response depends on the efficiency of the activation pathway.

Question 28Foundational Knowledge and Terminology

A pharmacogene carries a variant that introduces a premature termination codon, and no functional protein is detected. Which term best describes the functional consequence of this variant?

  1. Loss-of-function variant Correct answer.
  2. Gain-of-function variant
  3. Copy number variant
  4. Synonymous variant

Explanation

A premature stop codon typically truncates the protein and abolishes its function, so the allele is classified as loss-of-function. Functional classification reflects the effect on protein activity, not merely the type of DNA change.

Question 29Foundational Knowledge and Terminology

A variant lies in a gene encoding a drug transporter and reduces transport of a substrate across a membrane, but the drug's target protein is unchanged. Which term best describes how this variant alters drug response?

  1. Pharmacokinetic alteration Correct answer.
  2. Pharmacodynamic alteration
  3. Idiosyncratic reaction
  4. Therapeutic index shift

Explanation

Transporters influence absorption, distribution, and elimination, so a variant that changes transport alters drug exposure at the target rather than the target's response. Such changes are pharmacokinetic because they affect what the body does to the drug.

Question 30Foundational Knowledge and Terminology

A pharmacogene has two common coding variants, each individually associated with altered enzyme activity. Which term describes the combined set of variants present on the same chromosome and inherited together?

  1. Genotype
  2. Phenotype
  3. Allele frequency
  4. Haplotype Correct answer.

Explanation

A haplotype is the specific combination of variants on a single chromosome that are inherited as a unit. Star allele nomenclature in pharmacogenetics is built on haplotypes, which is why two patients with the same gene can carry different allele combinations and different activity.

Question 31Core Principles and Frameworks

Under PBP (protocol-based prescribing) governance, which document defines the clinical criteria, authorized prescriber group, and monitoring requirements for a specific therapy?

  1. The approved protocol or treatment guideline Correct answer.
  2. The drug's summary of product characteristics
  3. The formulary monograph
  4. The pharmacy dispensing standard operating procedure

Explanation

A protocol is the controlled document that sets out eligibility criteria, who may prescribe or initiate, and the monitoring and review requirements for a defined therapy. Formulary monographs and product information support decisions but do not authorize practice, and dispensing SOPs govern pharmacy process rather than prescribing authority.

Question 32Core Principles and Frameworks

A protocol-based prescribing framework is best described as which of the following?

  1. A system where prescribers may initiate designated medicines only within pre-agreed criteria and governance Correct answer.
  2. A system where any registered prescriber may prescribe any medicine within their competence
  3. A system where prescribing is delegated to unregistered assistants under supervision
  4. A system where pharmacists take over all prescribing decisions from physicians

Explanation

PBP is a governance model: designated medicines or classes are initiated by specified prescriber groups against pre-agreed criteria, with audit and accountability built in. It does not create open-ended prescribing rights, nor does it transfer whole clinical responsibility to pharmacy or to unregistered staff.

Question 33Core Principles and Frameworks

Which element is essential before a medicine can be added to a PBP list?

  1. Evidence that the medicine is the cheapest option in its class
  2. A documented risk assessment with agreed criteria, monitoring, and audit arrangements Correct answer.
  3. A patient information leaflet translated into every local language
  4. Agreement from the manufacturer to supply at a discount

Explanation

Admission to a protocol list requires a documented assessment of benefit, risk, and governance, including eligibility criteria, monitoring, and audit. Cost and supplier arrangements may inform the decision but are not the defining safety prerequisite.

Question 34Core Principles and Frameworks

In a PBP framework, what is the primary purpose of a defined audit cycle?

  1. To satisfy the manufacturer's marketing requirements
  2. To compare prescribing volumes between competing hospitals
  3. To verify that prescribing matches the agreed criteria and to feed improvements back into the protocol Correct answer.
  4. To identify individual clinicians for disciplinary action

Explanation

Audit under PBP is a quality-improvement mechanism: it tests practice against the agreed standard, identifies variation, and drives revision of the protocol or the training around it. Its purpose is system learning rather than punishment or external comparison.

Question 35Core Principles and Frameworks

Which statement correctly distinguishes a patient group direction (PGD) from a protocol-based prescribing arrangement?

  1. A PGD is written by the manufacturer, whereas PBP is written by the clinician
  2. A PGD applies only to controlled drugs, whereas PBP applies to all medicines
  3. A PGD authorizes supply or administration to an unnamed patient group by specified registered staff, whereas PBP concerns prescribing decisions for individual patients Correct answer.
  4. A PGD removes the need for any clinical assessment before supply

Explanation

A PGD is a specific legal mechanism allowing named staff groups to supply or administer a medicine to patients who meet defined criteria, without an individual prescription. PBP concerns the prescribing decision itself, so the two instruments have different legal bases and scope.

Question 36Core Principles and Frameworks

A protocol permits initiation of a medicine by a defined prescriber group, but a patient falls outside the stated inclusion criteria. What is the most appropriate action?

  1. Initiate anyway and document the deviation retrospectively
  2. Do not initiate under the protocol and refer for an individualized prescribing decision Correct answer.
  3. Modify the protocol criteria locally to fit the patient
  4. Ask a colleague to sign the protocol form on your behalf

Explanation

Protocols authorize action only within their stated criteria; outside them, the prescriber must step outside the protocol pathway and obtain an individualized decision from an appropriate prescriber. Retrospective justification, proxy signing, or unilateral amendment bypasses governance and is unsafe.

Question 37Core Principles and Frameworks

Which governance body is typically accountable for approving and periodically reviewing PBP protocols within an organization?

  1. The procurement department alone
  2. The individual prescriber who wrote the draft
  3. The medicines management or therapeutics committee with clinical governance oversight Correct answer.
  4. The external drug manufacturer's medical affairs team

Explanation

Protocols require multidisciplinary approval and scheduled review, usually through a medicines management or therapeutics committee operating under clinical governance. Individual authors, procurement, and manufacturers may contribute but cannot hold approval accountability.

Question 38Core Principles and Frameworks

A PBP protocol for an anticoagulant requires baseline renal function and a follow-up review at four weeks. A prescriber initiates therapy without a baseline creatinine result. Which principle has been breached?

  1. The dispensing accuracy standard
  2. The protocol's mandatory pre-initiation safety criteria Correct answer.
  3. The formulary restriction on high-cost medicines
  4. The consent documentation requirement

Explanation

Mandatory pre-initiation criteria in a protocol are safety conditions, not optional guidance; omitting baseline renal assessment removes the information needed to judge dose and risk. The other options refer to unrelated governance areas.

Question 39Core Principles and Frameworks

Which of the following best explains why PBP frameworks require explicit documentation of the prescriber's competence?

  1. Authority to prescribe under a protocol is linked to demonstrated competence for that specific medicine or patient group Correct answer.
  2. Competence records are required only for controlled drugs
  3. Documentation of competence replaces the need for clinical guidelines
  4. Competence is recorded to support billing and reimbursement

Explanation

PBP grants authority conditionally: the practitioner must be competent for the specific medicine and population covered by the protocol. Recording competence supports accountability and identifies training needs; it does not replace guidelines or serve a billing purpose.

Question 40Core Principles and Frameworks

A hospital wants to introduce PBP for a high-risk medicine. Which sequence best reflects sound implementation?

  1. Protocol drafting, immediate rollout, then retrospective audit
  2. Stakeholder engagement, risk assessment, protocol drafting, approval, training, pilot, audit, and review Correct answer.
  3. Pilot on one ward, then approval if no incidents occur
  4. Manufacturer-led training, then protocol drafting by pharmacy alone

Explanation

Sound implementation front-loads engagement and risk assessment, secures formal approval, trains users, and tests the pathway before full rollout, with audit feeding scheduled review. Approval before use and prospective governance are central to PBP.

Question 41Core Principles and Frameworks

Which outcome measure would best indicate that a PBP protocol is functioning as intended?

  1. The average cost per prescription compared with last year
  2. The proportion of initiations meeting all documented eligibility and monitoring criteria Correct answer.
  3. The number of clinicians who have read the protocol document
  4. The total number of prescriptions written under the protocol

Explanation

Protocol performance is judged by adherence to its criteria, including eligibility and monitoring, because that is what protects patients. Volume, cost, and readership are contextual indicators but do not demonstrate correct use.

Question 42Core Principles and Frameworks

In PBP terminology, what does 'inclusion criteria' refer to?

  1. The medicines that may be prescribed under the protocol
  2. The list of prescribers permitted to use the protocol
  3. The patient characteristics that must be present for the protocol to be used Correct answer.
  4. The monitoring tests required after initiation

Explanation

Inclusion criteria describe the clinical and demographic features a patient must have for the protocol pathway to apply. Prescriber lists, medicine lists, and monitoring schedules are separate components of the protocol document.

Question 43Core Principles and Frameworks

A patient meets the inclusion criteria for a protocol but has a documented allergy listed in the exclusion criteria. How should the prescriber proceed?

  1. Ask the patient to confirm whether the allergy is genuine before proceeding
  2. Proceed at a reduced dose to limit allergy risk
  3. Proceed because the inclusion criteria are satisfied
  4. Treat the exclusion criterion as decisive and pursue an alternative management plan Correct answer.

Explanation

Exclusion criteria override inclusion criteria; if any exclusion applies, the protocol pathway is closed. Dose reduction or patient reassurance does not neutralize a documented contraindication, and an alternative plan is required.

Question 44Core Principles and Frameworks

Which statement about the legal status of a PBP protocol is most accurate?

  1. It has the same legal force as primary legislation
  2. It is a locally approved governance instrument that must operate within national prescribing law and professional standards Correct answer.
  3. It is advisory only and carries no accountability
  4. It transfers legal liability for prescribing to the organization

Explanation

A protocol is an internal governance instrument; it must sit within, and cannot override, national law and professional regulation. It does not create legislation, is not merely advisory, and does not shift individual professional accountability to the organization.

Question 45Core Principles and Frameworks

A pharmacist working under PBP identifies that a protocol's monitoring interval conflicts with current national guidance. What is the most appropriate response?

  1. Continue to follow the approved protocol and escalate the discrepancy through governance for review Correct answer.
  2. Stop all prescribing under the protocol indefinitely
  3. Adjust the monitoring interval for individual patients without documentation
  4. Immediately apply the national guidance and ignore the protocol

Explanation

The approved protocol remains the operative standard until formally revised, but a known discrepancy must be escalated so governance can review and amend it. Unilateral deviation or silent individual adjustment undermines consistency and accountability.

Question 46Core Principles and Frameworks

Which scenario most clearly falls outside the legitimate scope of a protocol-based prescribing service?

  1. Initiating a routine medicine for a patient who meets all criteria
  2. Continuing therapy for a stable patient within the monitoring schedule
  3. Prescribing a newly diagnosed complex condition that requires specialist assessment and ongoing titration Correct answer.
  4. Supplying a protocol medicine to an eligible patient after assessment

Explanation

PBP is designed for defined, predictable clinical situations, not for complex diagnosis or open-ended specialist titration. Cases requiring specialist judgment should be referred rather than forced through a protocol pathway.

Question 47Core Principles and Frameworks

What is the main purpose of recording the protocol version and approval date on a PBP prescription record?

  1. To satisfy the manufacturer's pharmacovigilance obligations
  2. To provide an audit trail linking the decision to the governance standard in force at the time Correct answer.
  3. To enable the pharmacy to calculate the medicine's cost
  4. To determine the patient's eligibility for reimbursement

Explanation

Version and approval date create traceability, allowing later review to confirm which standard governed a decision and whether it was current. This supports audit and accountability rather than costing, pharmacovigilance, or reimbursement.

Question 48Core Principles and Frameworks

A PBP service is being designed for a rural clinic with limited laboratory access. Which design consideration is most important?

  1. Maximizing the number of medicines on the protocol list to improve access
  2. Delegating protocol decisions to the least busy staff member
  3. Removing monitoring requirements to simplify the pathway
  4. Selecting protocol medicines and monitoring requirements that are feasible with available local capacity Correct answer.

Explanation

A protocol is only safe if its monitoring can actually be delivered locally; design must match the medicine to available capacity. Expanding the list or dropping monitoring creates risk rather than access, and staffing decisions must reflect competence.

Question 49Core Principles and Frameworks

Which of the following is a recognized benefit of protocol-based prescribing?

  1. Complete removal of prescribing errors
  2. Reduction of the need for patient consent
  3. Faster access to defined treatments for eligible patients with consistent standards of care Correct answer.
  4. Elimination of the need for clinical judgment

Explanation

PBP streamlines access to specified treatments while standardizing criteria and monitoring across practitioners. It does not remove clinical judgment, eliminate errors, or alter consent requirements.

Question 50Core Principles and Frameworks

A protocol specifies that only prescribers who have completed accredited training may initiate a medicine. A newly qualified prescriber has not yet completed training. What is the correct position?

  1. They may initiate if a trained colleague agrees verbally
  2. They may initiate because registration confers general prescribing rights
  3. They may initiate once they have read the protocol document independently
  4. They may not initiate under the protocol until training is completed and recorded Correct answer.

Explanation

Protocol authority is conditional on the specified training being completed and evidenced; general registration does not substitute for it. Verbal cover or self-directed reading does not satisfy an explicit competence requirement.